Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Deckelmann, Regina
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1719	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	09/25	09/25
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease	Recruiting	1	130	Europe, US	GSK3862995B, Placebo	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	06/26	06/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Deckelmann, Regina
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1719	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	09/25	09/25
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease	Recruiting	1	130	Europe, US	GSK3862995B, Placebo	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	06/26	06/26